Previous 10 | Next 10 |
2023-04-27 09:17:33 ET Zai Lab ( NASDAQ: ZLAB ) signed a licensing agreement with MediLink Therapeutics for a next generation anti-body-drug conjugate (ADC) to treat cancer cancer. Zai said via the collaboration, it has expanded its lung cancer franchise and global oncology pi...
SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink). MediLink is an innovative drug development company focusing ...
SHANGHAI and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of ...
SHANGHAI, China and CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2023 and recent corporate updates after the closing of the U.S. equity markets on May 9, 2023. The Com...
SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data including a translational and biomarker data analysis from its internal oncology discovery program ZL-1211 at the upcoming 2023 American Association for Cancer Resear...
2023-03-26 07:45:00 ET There's a good chance that Zai Lab 's (NASDAQ: ZLAB) stock will make a journey into the stratosphere in the next few years, and that means growth-hungry investors should consider loading up on its shares, and soon. Whereas other mid-cap biotechs of roughly...
2023-03-23 07:54:57 ET Royalty Pharma ( NASDAQ: RPRX ) has acquired PureTech Health’s ( NASDAQ: PRTC ) royalty interest in KarXT, the lead investigational product of Karuna Therapeutics ( NASDAQ: KRTX ), for up to $500M, according to a Thursday press rel...
2023-03-21 16:01:16 ET Karuna Therapeutics ( NASDAQ: KRTX ) dropped for the second straight session on Tuesday to reach a seven-month low, while Wall Street brushed off safety results in a Phase 3 readout for its schizophrenia candidate KarXT, co-developed with Zai Lab Limited (...
2023-03-21 06:49:26 ET Following a ~5% drop in the prior session despite a trial win, Karuna Therapeutics ( NASDAQ: KRTX ) shares continued to tumble in the pre-market trading Tuesday after announcing the start of a $400.0M offering of its common stock. The underwritten pu...
Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a side effect profile substantially consistent with previous trials of ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...